Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 13, 2024

SELL
$26.56 - $33.55 $73,040 - $92,262
-2,750 Reduced 3.85%
68,744 $2.22 Million
Q4 2023

Feb 13, 2024

BUY
$18.35 - $34.12 $383,166 - $712,459
20,881 Added 41.26%
71,494 $2.05 Million
Q3 2023

Nov 13, 2023

BUY
$25.17 - $35.05 $45,255 - $63,019
1,798 Added 3.68%
50,613 $1.4 Million
Q2 2023

Aug 04, 2023

BUY
$20.28 - $27.0 $138,735 - $184,707
6,841 Added 16.3%
48,815 $1.31 Million
Q1 2023

May 12, 2023

BUY
$20.76 - $30.09 $131,037 - $189,928
6,312 Added 17.7%
41,974 $909,000
Q4 2022

Feb 10, 2023

BUY
$17.68 - $25.53 $5,498 - $7,939
311 Added 0.88%
35,662 $849,000
Q3 2022

Nov 14, 2022

BUY
$17.46 - $26.0 $102,158 - $152,126
5,851 Added 19.83%
35,351 $697,000
Q2 2022

Aug 12, 2022

BUY
$14.54 - $27.17 $159 - $298
11 Added 0.04%
29,500 $575,000
Q1 2022

May 13, 2022

SELL
$17.31 - $26.4 $35,935 - $54,806
-2,076 Reduced 6.58%
29,489 $752,000
Q4 2021

Feb 11, 2022

SELL
$24.35 - $33.7 $22,986 - $31,812
-944 Reduced 2.9%
31,565 $794,000
Q3 2021

Nov 12, 2021

SELL
$23.95 - $33.41 $18,489 - $25,792
-772 Reduced 2.32%
32,509 $894,000
Q2 2021

Aug 13, 2021

BUY
$29.0 - $47.44 $243,194 - $397,831
8,386 Added 33.69%
33,281 $1.06 Million
Q1 2021

May 07, 2021

BUY
$37.21 - $54.43 $91,871 - $134,387
2,469 Added 11.01%
24,895 $1.14 Million
Q4 2020

Feb 12, 2021

SELL
$30.19 - $45.49 $19,412 - $29,250
-643 Reduced 2.79%
22,426 $888,000
Q3 2020

Nov 04, 2020

BUY
$22.61 - $34.8 $318,936 - $490,888
14,106 Added 157.38%
23,069 $803,000
Q2 2020

Aug 12, 2020

BUY
$19.65 - $39.34 $11,829 - $23,682
602 Added 7.2%
8,963 $283,000
Q1 2020

May 04, 2020

BUY
$20.0 - $34.08 $167,220 - $284,942
8,361 New
8,361 $183,000

Others Institutions Holding RVMD

About Revolution Medicines, Inc.


  • Ticker RVMD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,697,600
  • Market Cap $3.8B
  • Description
  • Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also d...
More about RVMD
Track This Portfolio

Track American International Group, Inc. Portfolio

Follow American International Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on American International Group, Inc. with notifications on news.